We are proud to announce that we have been accepted as a member company of JLABS Singapore, an innovation hub established jointly by Johnson & Johnson’s external innovation group and the Singapore Economic Development Board (EDB).

JLABS is the world’s largest network of open innovation ecosystems, empowering emerging life science companies with access to expertise, strategic partnerships, and venture connections across the pharmaceutical, biotechnology, and medical technology sectors. More information available here: https://jnjinnovation.com/jlabs

Leveraging our proprietary RNA-targeting drug discovery technology, we are dedicated to developing treatments for rare genetic diseases. By joining JLABS Singapore, we aim to leverage the community’s key expertise, resources and industry connections to accelerate our research and development efforts and enhance corporate value.

This milestone marks a significant step in our global expansion and our dedication to enhancing the lives of patients worldwide. We look forward to sharing our progress as we move ahead.